Shares of Mylan (MYL) were higher Tuesday after a U.S. District Court rejected competitor Teva Pharmaceuticals' (TEVA) claims of patent infringement on a drug used to treat multiple sclerosis. This opens the door for Mylan which has been working on a more affordable, generic version of the drug. This comes as embattled EpiPen-maker said it was under investigation by the Federal Trade Commission for violation of antitrust laws. However, the company released a statement saying, "Mylan received an information request from the FTC months ago as part of a preliminary investigation. Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit."
More from Video
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.